Histogenics Corp (HSGX) was Reiterated by Needham to “Buy” while Lowering the Price Target of the company shares to $ 8 from a previous price target of $11 . Needham advised their investors in a research report released on Sep 19, 2016.
Many Wall Street Analysts have commented on Histogenics Corp. Shares were Reiterated by Needham on Sep 19, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $11 .
On the company’s financial health, Histogenics Corp reported $-0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Aug 11, 2016. Analyst had a consensus of $-0.60.During the same quarter in the previous year, the company posted $-0.58 EPS.
Histogenics Corp closed down -0.23 points or -6.69% at $3.21 with 131,378 shares getting traded on Friday. Post opening the session at $3, the shares hit an intraday low of $2.82 and an intraday high of $3.23 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s lead product candidate is NeoCart. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The product has completed Phase II clinical trials and is being investigated in a Phase III clinical trial as a first-line therapy for thickness knee chondral lesions in skeletally mature adults age 18 to 55. The Company uses regenerative medicine platform to develop its products. The Company’s regenerative medicine platform is comprises bioengineering materials sciences as well as molecular and cellular biology technologies that can be utilized individually or in a variety of combinations to treat musculoskeletal-related conditions.